Back to search results

Burn Study: Tranexamic Acid Versus Thrombin in Skin Grafts

This study is looking at two different medications, tranexamic acid and Thrombin-JMI®, to see which one works better or just as well at preventing bleeding (hematoma formation) after a split thickness skin graft. A split thickness skin graft is a surgery where skin is taken from an uninjured part of your body to cover a burn wound. Researchers want to see if tranexamic acid can be a good, less expensive alternative to Thrombin-JMI®, which is currently the standard treatment. You might be able to join if you are 18 or older, speak English or Spanish, and have certain types of flame or scald burn injuries. The study will measure how many people get hematomas, how well the skin graft takes, and if anyone needs another surgery. The current recruitment status is unclear, with a plan to enroll 62 participants.

Study design
This is an interventional study where participants will be randomly assigned to either the control group (receiving Thrombin-JMI®) or the experimental group (receiving tranexamic acid). The planned enrollment is 62 participants.
What's involved
You will undergo a split thickness skin graft procedure. Before surgery, you will provide informed consent. During surgery, either Thrombin-JMI® or tranexamic acid will be applied to your wound.
Compensation
Not stated in the trial record.
Follow-up
The study will measure outcomes at post-operative day fourteen, plus or minus two days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06379724

Burn Study- Tranexamic Acid Versus Thrombin in Split Thickness Skin Graft

Recruiting
PHASE4Ages 18+InterventionalTreatment
University of Kansas Medical Center
~62 participants
Updated 2026-08-27 on ClinicalTrials.gov
What's tested:Tranexamic acidThrombin JMIskin graft

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The number of participants with hematoma occurrence
Measured over Post-operative day fourteen, plus or minus two days
+2 more outcomes measured

Conditions

Burns
Skin Graft Complications

Explore related trials

BurnSkin Graft Complications

Where it's being run

1 sites across 1 states
Kansas1

Study leadership

  • Dhaval Bhavsar, MBBS · PRINCIPAL_INVESTIGATOR · University of Kansas Medical Center

Who to contact

Jessica Reynolds, BSN
[email protected]
913-588-5000 · ext. 0044
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

English or Spanish speaking
Flame or scald burn injury
\<=10% total body surface area (TBSA) partial thickness
\<= 5% total body surface area (TBSA) deep partial or full thickness
Skin graft harvested at 1/12 inch depth, meshed 1:1 or pie crusted if the area is a small functional area

Exclusion

\>10% total body surface area (TBSA) partial thickness burn
\>5% total body surface area (TBSA )surgical area of burn injury (deep partial or full thickness injury)
Traumatic or chemical burn mechanism
Patients on immunosuppression
Uncontrolled diabetes
Known diagnosis of peripheral vascular disease or diagnosis at time of injury
Pregnant women
Patients with acquired defective color vision
Patients with subarachnoid hemorrhage
Patients with active intravascular clotting or known hypersensitivity reactions to tranexamic acid
Inability to give informed consent

What this trial measures

  • The number of participants with hematoma occurrencePost-operative day fourteen, plus or minus two days

    dichotomous endpoint

  • The rate of percentage of graft take adherence amongst participantsPost-operative day fourteen, plus or minus two days

    continous endpoint

  • Comparison of number of participants that require re-operationPost-operative day fourteen, plus or minus two days

    dichotomous endpoint